ClinicalTrials.gg
CompletedNCT05916560Updated Apr 18, 2025

A Study of LY3437943 in Participants With Impaired and Normal Liver Function

A Phase 1 interventional study of LY3437943 in Healthy and Hepatic Insufficiency, sponsored by Eli Lilly and Company. Completed at 5 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-18.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hepatic Insufficiency by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Hepatic Insufficiency · Eli Lilly and Company.

Enrollment
2nd of 12
43 · median 34
Started
2023
with 1 other
Phase 1
12 of 12
2 open now
Registered
8th of 12
by date

Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, this one is the 2nd largest by enrollment, is one of 2 that started in 2023, is one of 12 in phase 1, and was the 8th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

2 of the 12 studies in Hepatic Insufficiency by Eli Lilly and Company are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hepatic Insufficiency by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function. The safety and tolerability of LY3437943 will also be evaluated. The study may last up to 9 weeks for each participant including the screening period.

03

Conditions studied

  • Healthy
  • Hepatic Insufficiency

Browse trials for

Keywords

  • Pharmacokinetics
  • Hepatic Impairment
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants:

  • Have a within the range 19.0 to 42.0 kilograms per meter squared (kg/m²), inclusive
  • Healthy or various degrees of hepatic impairment depending on the study group

Exclusion criteria

Exclusion Criteria:

Participants with hepatic impairment:

  • Have or are anticipating an organ transplant within the next 6 months
  • Requires needle evacuation of ascites fluid more than 2 times per month
  • Have had variceal bleeding within 3 months of check-in, unless the participant has undergone a successful banding procedure; in that case, may check-in from 1 month after the banding procedure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    LY3437943 (Normal Hepatic Function)

    LY3437943 administered subcutaneously (SC).

    Drug: LY3437943

  • Experimental
    LY3437943 (Severe Hepatic Impairment)

    LY3437943 administered SC.

    Drug: LY3437943

  • Experimental
    LY3437943 (Moderate Hepatic Impairment)

    LY3437943 administered SC.

    Drug: LY3437943

  • Experimental
    LY3437943 (Mild Hepatic Impairment)

    LY3437943 administered SC.

    Drug: LY3437943

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943

    PK: AUC0-∞ of LY3437943

    Time frame: Predose up to 30 days postdose

  2. PK: Maximum observed concentration (Cmax) of LY3437943

    PK: Cmax of LY3437943

    Time frame: Predose up to 30 days postdose

07

Study locations

5 sites
  • Arizona Clinical Trials - Chandler
    Chandler, Arizona 85225, United States
  • Accel Research Sites- Clinical Research Unit
    DeLand, Florida 32720, United States
  • Advanced Pharma Clinical Research
    Miami, Florida 33147-4040, United States
  • American Research Corporation at Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Mar 2025, 19 months.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 19 months is above that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2023
First posted
Jun 23, 2023
StartActual
Jul 13, 2023
Primary completionActual
Mar 2, 2025
CompletionActual
Mar 2, 2025
Last update
Apr 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05916560
Responsible party
Sponsor
First posted
Jun 23, 2023
Start date
Jul 13, 2023
Primary completion
Mar 2, 2025
Completion
Mar 2, 2025
Last update
Apr 18, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion